Navigation Links
Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office
Date:8/24/2009

PISCATAWAY, N.J., Aug. 24 /PRNewswire-FirstCall/ -- Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for Milestone's U.S. patent application directed to the use of its disposable hand piece for fluid administration. Milestone's proprietary, award-winning hand piece is an instrument currently utilized in conjunction with the Company's commercially available Computer-Controlled Local Anesthetic Delivery (C-CLAD) systems, including the STA Single Tooth Anesthesia System(TM), CompuDent(R) and CompuMed(R).

Dr. Mark Hochman, Director of Clinical Affairs at Milestone Scientific, noted, "We are very pleased with the U.S. Patent Office's decision to recognize the uniqueness of our invention. Moreover, obtaining patent protection for this particular component of our C-CLAD technology was an important step in further securing our position as the industry leader in the delivery of subcutaneous drug delivery."

A Notice of Allowance generally completes the substantive examination of a patent application. The normal process which results in a final issuance of a U.S. patent involves several administrative steps that are typically completed in due course following the issuance of such a Notice. To date, Milestone has been awarded a total of 21 U.S. utility and design patents relating to its C-CLAD technologies.

According to Leonard Osser, Milestone's Chairman and Interim Chief Executive Officer, "This Notice is a strong validation of Milestone's technological leadership and innovation, and demonstrates our team's proven ability to pioneer important new components and mechanisms that add material value to our growing intellectual property platform."

About Milestone Scientific Inc.

Headquartered in Piscataway, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative technological solutions for the medical and dental markets. Central to the Company's IP platform and product development strategy is its patented CompuFlo(R) technology for the improved and painless delivery of local anesthetic. Specifically, CompuFlo is a computer-controlled, pressure sensitive infusion, perfusion, suffusion and aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the advanced delivery and removal of a wide array of fluids. The STA Single Tooth Anesthesia System(TM), a computer-controlled local anesthesia delivery system, uses this technology to provide dentists with audible and visual signals as to in-tissue pressure. Milestone's existing painless injection systems are currently sold in 25 countries. For more information on these and other innovative Milestone products, please visit the Company's web site found at www.milestonescientific.com and www.STAis4U.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of the Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2008. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

                       FOR MORE INFORMATION, PLEASE CONTACT:
                       Elite Financial Communications Group
                Dodi Handy, President and CEO (Twitter: @dodihandy)
          For Media Inquiries: Kathy Addison, Director, Elite Media Group
                             (Twitter: @kathyaddison)
                   +1-407-585-1080 or via email at mlss@efcg.net


'/>"/>
SOURCE Milestone Scientific Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CAS REGISTRY(SM), the Global Standard for Chemical Research, Approaches 50 Millionth Registration Milestone
2. ENT and Allergy Opens New Office in Hoboken, New Jersey…Practice Achieves Milestone by Bringing on its 100th Physician
3. Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports
4. Milestone Scientific Reports 44% Increase in Revenues in First Six Months of 2009 Compared to Prior Year
5. Cardiome Achieves Milestone From Collaboration With Merck Co., Inc.
6. AccuVein Achieves Quality System Milestone
7. Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec
8. Volcano Achieves Major Milestone in Japan Direct Sales Initiative With Signing of Termination Agreement With Goodman
9. DaVitas Award-Winning Training Program for New Teammates Reaches Milestone With 100th DaVita Academy in Baltimore, Maryland
10. BioGlue(R) Surgical Adhesive Hits 500,000 Procedure Milestone Worldwide, Company Data Indicates
11. Milestone Scientific Expands Global Sales Strategy to Enhance Penetration of International Dental Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... FL (PRWEB) , ... February 13, 2016 , ... The ... environmental impact of American businesses. , The increasingly modern world of instantaneous consumption ... often on non-renewable energy sources such as oil and coal, which pollutes our air, ...
(Date:2/13/2016)... ... 2016 , ... When an Au Pair comes all the way around the world ... for and they are often worried things won’t go well. More often than not, however, ... Au Pair of the Year winner’s all commented how their Au Pairs have become a ...
(Date:2/12/2016)... ... February 12, 2016 , ... According to an article published February ... a significant portion of hernia repairs throughout the United States. Commenting on this article, ... notes that this trend has not only been expected, but it seems to be ...
(Date:2/12/2016)... Seattle, WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens ... technologies for low-resource settings. The partnership will recruit top students from U.S. ...
(Date:2/12/2016)... VA (PRWEB) , ... February 12, 2016 , ... ... Feb. 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... in the life cycle of pharmaceutical products, garnering increased attention from all stakeholders ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016  This month,s issue of the ... takes an in-depth look at various causes and ... prescription drug spending, which has generated significant public outrage ... Editor-in-Chief Laura E. Happe , PharmD, MPH. ... , PharmD, MPH. --> In 2014 prescription ...
(Date:2/12/2016)... MONTREAL , February 12, 2016 ... sofern nicht anders vermerkt)   ... Unternehmens http://www.telestatherapeutics.com abrufbar.    ... Website des Unternehmens http://www.telestatherapeutics.com ... Inc. (TSX:TST; PNK:BNHLF) veröffentlichte heute seinen Konzernabschluss ...
(Date:2/12/2016)... Feb. 12, 2016  Sequent Medical, Inc. announced today ... to evaluate the safety and effectiveness of the WEB™ ... ruptured intracranial aneurysms.  Prof Laurent Spelle , MD, ... Paris, France and Principal Investigator of ... France and Germany.  Although patients with ...
Breaking Medicine Technology: